LONG-R3-IGF-I is an effective alternative to recombinant insulin for cell culture applications.
As a consequence of this decision, the production at Novozymes Biopharma Australia will be closed down mid-2009 after the transfer. The center of excellence in cell culture R&D in Adelaide will continue.
“As a part of our ongoing efforts to optimize production, we are now consolidating by moving this product to our pharmaceutical site in Sweden. At the same time our strategy is to build a strong product portfolio within the cell culture market and to build an R&D group with some of the best people in the field. The product LONG-R3-IGF-I and Novozymes Biopharma Australia play important roles in that strategy,” says Anders Gram, VP of Pharma Operations.